Compare Stocks

→ Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CEMI Chembio Diagnostics	$0.46	$0.43	$0.19 ▼ $1.24	$16.71M	1.85	661,416 shs	351,642 shs
CLSD Clearside Biomedical	$1.32 +4.8%	$1.45	$0.65 ▼ $2.12	$98.63M	2.29	345,278 shs	329,091 shs
CTIC CTI BioPharma	$9.09	$9.06	$4.01 ▼ $9.10	$1.20B	0.83	4.50 million shs	N/A
TORC resTORbio	$2.03 -11.0%	$12.16	$0.86 ▼ $10.50	$73.82M	2.43	1.15 million shs	929,922 shs
ZYNE Zynerba Pharmaceuticals	$1.30 +2.4%	$1.30	$0.25 ▼ $1.40	$70.12M	1.32	515,333 shs	862,700 shs

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CEMI Chembio Diagnostics	0.00%	0.00%	0.00%	0.00%	+0.89%
CLSD Clearside Biomedical	+9.57%	+1.61%	-19.23%	-2.33%	+12.50%
CTIC CTI BioPharma	0.00%	0.00%	0.00%	0.00%	+102.90%
TORC resTORbio	0.00%	+1.86%	+12.31%	-20.07%	-64.33%
ZYNE Zynerba Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+213.25%

SHOCKING Crypto Leak… (Ad)

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CEMI Chembio Diagnostics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CLSD Clearside Biomedical	2.9414 of 5 stars	3.5	5.0	0.0	0.0	2.6	1.7	0.6
CTIC CTI BioPharma	0.0443 of 5 stars	1.0	0.0	0.0	0.0	0.6	1.7	0.6
TORC resTORbio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZYNE Zynerba Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CEMI Chembio Diagnostics	N/A	N/A	N/A	N/A
CLSD Clearside Biomedical	3.00	Buy	$4.75	259.85% Upside
CTIC CTI BioPharma	2.00	Hold	$9.00	-0.99% Downside
TORC resTORbio	N/A	N/A	N/A	N/A
ZYNE Zynerba Pharmaceuticals	2.00	Hold	$1.11	-14.62% Downside

Current Analyst Ratings

Latest ZYNE, CLSD, CTIC, CEMI, and TORC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/11/2024	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
3/14/2024	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
3/13/2024	CLSD Clearside Biomedical	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00
3/13/2024	CLSD Clearside Biomedical	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00 ➝ $4.00

(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CEMI Chembio Diagnostics	$48.34M	0.35	N/A	N/A	$0.48 per share	0.95
CLSD Clearside Biomedical	$8.23M	11.98	N/A	N/A	($0.25) per share	-5.28
CTIC CTI BioPharma	$53M	22.62	N/A	N/A	($0.14) per share	-64.93
TORC resTORbio	N/A	N/A	N/A	N/A	$2.24 per share	N/A
ZYNE Zynerba Pharmaceuticals	N/A	N/A	N/A	N/A	$1.01 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CEMI Chembio Diagnostics	-$23.29M	-$1.20	N/A	∞	N/A	-47.03%	-113.57%	-38.22%	N/A
CLSD Clearside Biomedical	-$32.49M	-$0.53	N/A	N/A	N/A	-394.91%	N/A	-85.31%	5/9/2024 (Estimated)
CTIC CTI BioPharma	-$92.99M	-$0.58	N/A	26.74	N/A	-91.38%	N/A	-55.82%	N/A
TORC resTORbio	-$82.74M	-$2.41	N/A	N/A	N/A	N/A	-78.12%	-71.63%	N/A
ZYNE Zynerba Pharmaceuticals	-$35.04M	-$0.80	N/A	N/A	N/A	N/A	-90.03%	-72.62%	N/A

Latest ZYNE, CLSD, CTIC, CEMI, and TORC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/12/2024	Q4 2023	CLSD Clearside Biomedical	-$0.10	-$0.08	+$0.02	-$0.08	$3.40 million	$6.35 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CEMI Chembio Diagnostics	N/A	N/A	N/A	N/A	N/A
CLSD Clearside Biomedical	N/A	N/A	N/A	N/A	N/A
CTIC CTI BioPharma	N/A	N/A	N/A	N/A	N/A
TORC resTORbio	N/A	N/A	N/A	N/A	N/A
ZYNE Zynerba Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CEMI Chembio Diagnostics	N/A	1.23	1.04
CLSD Clearside Biomedical	N/A	4.42	4.42
CTIC CTI BioPharma	N/A	1.27	1.26
TORC resTORbio	N/A	20.69	20.69
ZYNE Zynerba Pharmaceuticals	N/A	3.43	3.43

Ownership

Institutional Ownership

Company	Institutional Ownership
CEMI Chembio Diagnostics	8.65%
CLSD Clearside Biomedical	18.75%
CTIC CTI BioPharma	91.45%
TORC resTORbio	46.19%
ZYNE Zynerba Pharmaceuticals	11.23%

Insider Ownership

Company	Insider Ownership
CEMI Chembio Diagnostics	3.30%
CLSD Clearside Biomedical	9.80%
CTIC CTI BioPharma	7.61%
TORC resTORbio	11.80%
ZYNE Zynerba Pharmaceuticals	13.04%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CEMI Chembio Diagnostics	337	36.73 million	35.51 million	Not Optionable
CLSD Clearside Biomedical	30	74.72 million	67.40 million	Optionable
CTIC CTI BioPharma	127	131.88 million	121.84 million	Optionable
TORC resTORbio	N/A	36.45 million	N/A	Not Optionable
ZYNE Zynerba Pharmaceuticals	25	53.94 million	46.91 million	Optionable

ZYNE, CLSD, CTIC, CEMI, and TORC Headlines

Source	Headline
	Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results finance.yahoo.com - October 31 at 7:57 AM
	Why Shares of Harmony Bioscience Are Falling on Friday fool.com - October 13 at 12:59 PM
	New Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder Therapies markets.businessinsider.com - October 11 at 9:47 AM
	HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE finance.yahoo.com - October 11 at 9:47 AM
	H.C. Wainwright analysts reiterates a Buy rating for Zynerba Pharmaceuticals Inc (ZYNE) knoxdaily.com - October 10 at 1:59 PM
	Analysts: ZYNE stock price target of $1.25 in 12 months knoxdaily.com - October 5 at 6:47 PM
	Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions finance.yahoo.com - October 4 at 7:33 PM
	Examining the Potential Price Growth of Zynerba Pharmaceuticals Inc (ZYNE) knoxdaily.com - October 2 at 3:14 PM
	20 Countries With Highest Rate of Epilepsy finance.yahoo.com - September 29 at 6:24 PM
	Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023 finance.yahoo.com - September 29 at 1:23 PM
	Harmony Biosciences extends deadline for Zynerba shareholders on up to $200M deal bizjournals.com - September 27 at 2:42 PM
	Zynerba Pharmaceuticals Inc [ZYNE] Investment Appeal on the Rise knoxdaily.com - September 25 at 8:15 PM
	Zynerba Pharmaceuticals Inc. (ZYNE) rating reiterates by H.C. Wainwright knoxdaily.com - September 20 at 12:12 PM
	Negative sentiment towards ZYNE reflected in surge in short interest knoxdaily.com - September 15 at 8:27 PM
	Insider Sell: President Terri Sebree Sells 12,401 Shares of Zynerba Pharmaceuticals Inc finance.yahoo.com - September 14 at 11:23 PM
	Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium finance.yahoo.com - September 14 at 6:23 PM
	Zynerba Pharmaceuticals Hit With Shareholder Suit in Pa. Over Allegedly Inadequate Proxy Statement law.com - September 11 at 4:04 PM
	Positive sentiment towards ZYNE reflected in decline in short interest knoxdaily.com - September 8 at 5:19 AM
	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTG, ZYNE, KLR bakersfield.com - August 31 at 5:00 PM
	HC Wainwright & Co. Downgrades Zynerba Pharmaceuticals (ZYNE) msn.com - August 16 at 4:20 AM
	Harmony Makes Rare Disease Play with Potential $200M Zynerba Buyout biospace.com - August 15 at 6:19 PM
	Zynerba Pharma (NASDAQ: ZYNE) up 300% - The contingents are worth how much? dhakatribune.com - August 15 at 6:19 PM
	Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans? finance.yahoo.com - August 15 at 6:19 PM
	Zynerba Pharmaceuticals Shares Soar on Harmony Biosciences Deal >ZYNE marketwatch.com - August 14 at 9:48 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Chembio Diagnostics

NASDAQ:CEMI

Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.

Clearside Biomedical

NASDAQ:CLSD

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

CTI BioPharma

NASDAQ:CTIC

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.

resTORbio

NASDAQ:TORC

Adicet Bio, Inc. is a biotechnology company which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

Zynerba Pharmaceuticals

NASDAQ:ZYNE

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial